Xoma - Biotechperle!! - Gutes Langfristinvestement

Seite 1 von 4
neuester Beitrag: 08.10.08 17:23
eröffnet am: 02.11.01 14:14 von: Fips17 Anzahl Beiträge: 84
neuester Beitrag: 08.10.08 17:23 von: baanbruch Leser gesamt: 8929
davon Heute: 1
bewertet mit 2 Sternen

Seite: 1 | 2 | 3 | 4 | 4   

02.11.01 14:14
2

1497 Postings, 7017 Tage Fips17Xoma - Biotechperle!! - Gutes Langfristinvestement

Charttechnisch..

Seit November 1999 befindet sich Xoma in einem sehr sehr gemütlichen aber stabilen Aufwärtstrend und wir befinden uns derzeit am unteren Ende des Trendkanals! kurzfristig könnten sich wieder größere Kurssprünge aufzeigen da das Papier ziemlich volatil ist aber Xoma hält trotz der großen Volatilität seine Aufwärtstrend konstant bei.... ich glaube die Zeit zum Einsteigen dürfte gut sein da auch die Stochastiken sich im überverkauften Bereich befinden!


Neue Analyse von Hornblower Fischer

gefunden bei: www.finanznachrichten.de


.2001
XOMA langfristig interessant
Hornblower Fischer  

Die Analysten von Hornblower Fischer sehen in XOMA (WKN 871239) ein aussichtsreiches Investment für langfristig orientierte Anleger.

XOMA entwickele und produziere proteinbasierte Therapeutika zur Behandlung von Infektionskrankheiten, Immundefekten und Krebs. Das Unternehmen könne eine breite Produktpipeline mit einer Reihe vielversprechender Wirkstoffkandidaten vorweisen. Der Haupthoffnungsträger von XOMA sei Xanelim. Xanelim sei ein monoklonaler Antikörper, der in der Primärindikation zur Behandlung der Schuppenflechte eingesetzt werde und im Zusammenarbeit mit Genentech entwickelt werde. Im Juni/Juli habe Xoma die Ergebnisse von zwei Phase III-Studien veröffentlicht. 597 Patienten seien mit einer wöchentlichen subkutanen Injektion behandelt und über einen Zeitraum von 12 bzw. 24 Wochen beobachtet worden.

Das Ergebnis sei hinsichtlich der Sicherheit und der Wirksamkeit von Xanelim beeindruckend gewesen, so sei es bei 75% der Patienten zu einer deutlichen Linderung der Symptome gekommen, ohne signifikante Nebenwirkungen zu beobachten. Anfang Oktober habe es aber einen Rückschlag im Vorfeld des für Ende diesen bzw. Anfang nächsten Jahres geplanten Zulassungsantrags gegeben. Da es sich aber bei der Beanstandung durch die FDA eher um eine Formalie handelte, gehen die Analysten von Hornblower Fischer davon aus, dass der endgültigen Marktzulassung von Xanelim Mitte 2003 nichts im Weg steht. Das Umsatzpotenzial belaufe sich auf jährliche 1,7-2,0 Mrd. US-Dollar.

Ein weiteres aussichtsreiches Medikament von Xoma sei das Anti-Infektivum Neuprex. Neuprex basiere auf dem menschlichen Abwehrprotein BPI (bactericidal/permeability-increasing protein), das Bakterien töten, Endotoxine (bakterielle Giftstoffe) neutralisieren und die Antibiotikawirkung steigern könne. Einsatzgebiete von Neuprex seien u.a. Meningokokkämie und Morbus Crohn. Bei der Meningokokkämie handele es sich um eine bakterielle Entzündung der Hirnhaut und des Rückenmarks, wodurch es zu hohem Fieber, Hautauschlag und Steifheit der Glieder kommen könne. Die Krankheit trete v.a. bei Kindern auf und könne unbehandelt aufgrund von Organausfällen schnell zum Tod führen. Neuprex habe im Frühjahr dieses Jahres bereits einen kleinen Rückschlag einstecken müssen, als das Unternehmen mit Experten der FDA die Ergebnisse der III. klinischen Tests diskutiert und die Zulassungsbehörde konstatiert habe, dass die bisher erhobenen Daten nicht für einen erfolgreichen Zulassungsantrag ausreichen würden.

Bemängelt worden sei dabei aber nicht die Wirksamkeit des Medikaments, sondern die Tatsache, dass es sich bei der Meningokokkämie um eine tödliche Krankheit handele, wodurch es schwierig sei, eine signifikante Zahl an Patienten für die klinischen Tests zu finden. Zur Zeit würden weitere Phase III-Tests laufen. Der Zeitplan für einen erneuten Zulassungsantrag sei aber noch nicht bekannt gegeben worden.

XOMA habe eine Marktkapitalisierung von rund 500 Mio. US-Dollar und verfüge derzeit über eine Mitarbeiterstab von 182 Professionals. Die Zahlen für das 2. Quartal 2001 hätten sich mit einem Verlust von 0,10 US-Dollar pro Aktie (Minus 6,6 Mio. USD) genau auf dem Vorjahresniveau bewegt. Auf der Umsatzseite habe das Unternehmen eine Steigerung von 2,3 Mio. US-Dollar auf 5,2 Mio. US-Dollar erzielen können. Die F&E-Ausgaben seien aufgrund der ausgeweiteten Phase III-Studien mit Xanelim in den ersten 6 Monaten dieses Jahr von 17,7 Mio. US-Dollar auf 21,6 Mio. US-Dollar im Vergleich zum Vorjahr gestiegen.

Man sehe in XOMA ein aussichtsreiches Investment für langfristig orientierte Anleger. Das Unternehmen sei sehr gut auf dem Markt positioniert und biete mit Xanelim und der restlichen Produktpipeline genügend Fantasie für erneute Kursanstiege. Aufgrund der Verzögerung bei der Marktzulassung von Xanelim stehe die Aktie momentan etwas im Abseits und bewege sich in einer Trading-Range zwischen 7-9 US-Dollar. Erste Positionen könnten auf diesem Niveau aufgebaut werden, für Anschlusskäufe sollte das Überwinden der 10 USD-Hürde abgewartet werden. Trotz seiner 20-jährigen Geschichte handele es sich bei XOMA um ein typisches Biotechnologieunternehmen.

Anleger sollten sich des spekulativen und volatilen Charakters der Branche bewusst sein und daher gute Nerven und einen Anlagehorizont von mindestens 3 Jahren haben, so die Analysten von Hornblower Fischer.



LG Fips17



PS: Kennt wer den Wert bzw. was haltet ihr von der charttechnischen Situation??  
Seite: 1 | 2 | 3 | 4 | 4   
58 Postings ausgeblendet.

23.05.03 17:42

25951 Postings, 6856 Tage Pichelraus mit 2,6 in FFM

Position seit 28.1. zu 3,- und NK 2,- endlich !

Gruß Pichel

 

23.05.03 19:23

3515 Postings, 7290 Tage baanbruchMann, da geht ja mächtig was ab!


Was hast Du da bloß losgetreten !

Monatelang fast gar nix, und jetzt tanzt der Bär
(oder vielleicht doch der Bulle ?)

Na ja, wenn Du nicht davon überzeugt warst.
Ich bin's!
Für so ein Almosen gebe ich kein Stück ab.
 

23.05.03 19:26

25951 Postings, 6856 Tage Pichelsollte damals nur ein kurzer zock sein ;-(

Gruß Pichel

 

27.05.03 22:12

3515 Postings, 7290 Tage baanbruchAlso, wahrscheinlich schwimmt DeCode nur auf


der aktuellen Biotope-Hysterie der Amis mit.

Möchte den geneigten Lesern trotzdem 2 nicht ganz unwichtige
News zu DCGN mitteilen.

In Island wurde vor kurzem gewählt und die neue Regierung
ist mehr oder weniger die alte.
Der alte/neue Premierminister ist als Gönner (Staatsgarantien und so)
von DeCode bekannt.

Trotz Entlassung von schon sehr vielen Mitarbeitern
wurde heute die Entlassung von weiteren 28 bekannt gegeben.
Diese kommen fast alle aus dem Computerbereich und nicht aus dem Labor.
Hiermit soll das weitere Aufzehren der liquiden Mittel bekämpft werden.

So, wenn sie sich vom aktuellen Kurs verdreifachen und der Dollar sich
erholt, dann wären sie zweistellig.
Kann nur noch 1 oder 2 Jahre dauern!

 

31.08.03 18:57

3515 Postings, 7290 Tage baanbruchWarum nur habe ich im März keine Xoma gekauft?

Wohl weil ich auch keine Avaya, keine Baader
keine Infor und keine DAB-Bank gekauft habe.

Blöde muss der Mensch sein.
Oder grottenschlechtes Timing haben!

(Wären jetzt 300% gewesen!)
 

24.09.03 00:30

3515 Postings, 7290 Tage baanbruchdeCode zieht an ! o. T.

24.09.03 18:20

3515 Postings, 7290 Tage baanbruchMach ma Fensta zu, es zieht noch immer ! o. T.

30.09.03 20:01

3515 Postings, 7290 Tage baanbruchNa, wer sagt´s denn ? Über 4 ! Weiter so! o. T.

17.10.03 16:37

3515 Postings, 7290 Tage baanbruchEs dekodiert sich! Lecker!

30% an einem Tag habe ich auch lange nicht
mehr gehabt.
Hoffentlich fällt nicht Montag wieder alles in sich zusammen.

(issich wegen news bezgl. Test mit Roche).
 

17.10.03 17:18

3515 Postings, 7290 Tage baanbruchDas blöde bei der Entwicklung heute ist,

dass ich die news schon vor Börseneröffnung
hätte lesen können, wenn ich nur nach USA gekuckt hätte.

Ob ich allerdings in BRD zu 4,40 heute morgen noch bedient
worden wäre, steht auf einem ganz anderen Blatt.

Na, Pichel, nu is zweistellig doch gar nicht mehr sooooooo
illusionär, oder ?

Gruß
baanbruch
 

20.10.03 12:37

3515 Postings, 7290 Tage baanbruchJetzt woll´n wer doch mal sehen !

Nach dem starken Anstieg am Freitag sind ja
eigentlich Gewinnmitnahmen zu erwarten.
Andererseits gab es gestern im hohen Norden
höchst interessante news, dass man nämlich
jetzt eine Datenbank über Krebsfälle der letzten
50 Jahre fertig habe.
Wenn der Umsatz in BRD nicht so gering wäre, würde
ich fast zum Nachfassen raten.

Mal sehen, ob ich richtig liege. Die 7 Dollar
könnten heute in USA fallen.
 

28.10.03 12:42

3515 Postings, 7290 Tage baanbruchSo, Xoma, jetzt lauf mal schön! (news!)

Reuters
UPDATE - Genentech, Xoma win psoriasis drug OK
Monday October 27, 9:08 pm ET
By Deena Beasley


(Adds company comments, background, byline)
LOS ANGELES, Oct 27 (Reuters) - The U.S. Food and Drug Administration (News - Websites) on Monday said it approved Genentech Inc.'s (NYSE:DNA - News) Raptiva as a treatment for moderate-to-severe psoriasis, a chronic disease marked by red, scaly patches of inflamed skin.

ADVERTISEMENT
 

Genentech, the No. 2 biotechnology company which co-developed the drug with Xoma Ltd. (NasdaqNM:XOMA - News), said it expects to start shipping Raptiva in mid-November. The drug, which is given once a week by self-injection, will have a wholesale acquisition cost of about $14,000 a year, the company said.

Clinical trials of Raptiva have shown that after 12 weeks of treatment, it reduced psoriasis symptoms by 75 percent or more in between 18 percent and 37 percent of patients.

The drug is an antibody engineered to inhibit the binding of immune system cells to other cells.

The FDA last January approved Biogen Inc.'s (NasdaqNM:BGEN - News) Amevive as the first biologic, or naturally occurring substance, to combat psoriasis.

Amgen Inc.'s (NasdaqNM:AMGN - News) rheumatoid arthritis drug Enbrel is under review by the regulatory agency as a treatment for the chronic skin condition and other companies, such as Johnson & Johnson (NYSE:JNJ - News) are also testing new psoriasis treatments.

The new drugs work by either blocking immune system molecules that trigger psoriasis or the inflammatory response that leads skin cells to reproduce excessively.

Amevive, which is given intravenously or by injection, suppresses immune system T-cells that play a central role in psoriasis. It is long-acting, but patients must be monitored due to concerns it might compromise their immune systems.

A spokeswoman for Genentech said the FDA did not require physician-monitoring of Raptiva, other than advising doctors to look out for a drop in blood platelets, which are necessary for blood to clot.

"Raptiva fills a gap in the marketplace ... it offers continuous control of psoriasis in a once-weekly injection," said Diane Parks, Genentech's manager of specialty biotherapeutics.

She expects Enbrel to be Raptiva's chief competition. "At the end of the day, there is room for two biologics in the market," Parks said.

Kevin Young, general manager of Amgen's inflammation unit, said he expects FDA approval of Enbrel in psoriasis next year. "Our balance between safety and efficacy is what dermatologists want," he said. "Starting patients on Raptiva, and especially stopping them, has its challenges."

Some side effects of Raptiva included headaches, chills, fever and nausea, and the drug increase the risk of infection. In addition, the psoriasis flared up when patients stopped taking the drug.

The exact cause of psoriasis is not known, but experts believe it is related to an overactive immune system that may contribute to the abnormal growth of skin cells.

A normal skin cell usually matures in a month and is shed from the skin's surface unnoticed, but a psoriatic skin cell takes only a few days to mature and move to the surface, and the cells pile up and form raised, red lesions.

Raptiva, estimated by analysts to eventually reach peak sales of about $400 million a year, is not expected to be a blockbuster drug for Genentech, but it would be Xoma's first commercial product.

The companies submitted the latest application to the FDA in December. They first sought approval last April, but the agency asked for confirmation that Genentech facilities could duplicate earlier batches of the drug without changing its chemical composition.




Email this story - Set a News Alert
 

29.10.03 22:53

3515 Postings, 7290 Tage baanbruchdeCode knackt die 7Dollar(und wird drüber bleiben)

Gute Zahlen:

Press Release Source: deCODE genetics


deCODE genetics Announces Third Quarter 2003 Financial Results
Wednesday October 29, 4:03 pm ET  
Higher Revenues, Streamlined Cost Structure Drive Positive Cashflow From Operations; Strengthened Cash Position Bolsters Resources for Product Development


REYKJAVIK, Iceland, Oct. 29 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN, Nasdaq Europe: DCGN) today reported consolidated financial results for the quarter ended September 30, 2003. A conference call to discuss the quarter's results will be webcast live tomorrow, Thursday, October 30, at 8am EST/1pm GMT (details below).
ADVERTISEMENT


Revenue for the third quarter, ended September 30, 2003, was $12.8 million, a 42% increase compared to the $9.0 million for the same period a year ago. This growth reflects the performance of deCODE's product development and service businesses, as well as milestone revenue achieved under the company's corporate alliances. For the first nine months of 2003, revenue was $35.1 million, an increase of 48% versus the $23.7 million for the first nine months of 2002. At the close of the third quarter the company had $13.5 million in deferred revenue, which will be recognized over future reporting periods.

Net loss for the third quarter 2003 was $1.3 million. Net loss for the third quarter of 2002 was $85.4 million, including $64.8 million of impairment, employee termination costs and other charges. Excluding these items, net loss for the third quarter 2002 was $20.6 million. Compared to this figure, net loss for the third quarter 2003 decreased by 94% versus the year ago period. For the first nine months of 2003 net loss decreased by 56% to $24.6 million compared to the $56.2 million for the first nine months of 2002, which is also exclusive of the charges in the latter period. Higher revenues and the introduction of significant operational efficiencies in the latter half of last year were the principal factors in these reductions.

Basic and diluted net loss per share decreased to $0.03 for the third quarter 2003 from $1.68 for the same quarter last year. Basic and diluted net loss per share for the first nine months of 2003 was $0.48, versus $2.50 for the first nine months of 2002. At the close of the third quarter the company had approximately 53.8 million shares outstanding.

Research and development expenses during the third quarter were $11.1 million, including a one-time, non-cash reversal of accrued license fees amounting to $3.2 million. Excluding this reversal, R&D expenses for the third quarter were $14.3 million, 40% lower than the $23.9 million in the third quarter 2002. For the first nine months of 2003, R&D expenses were $47.5 million. Excluding the one-time reversal in the third quarter, R&D expenses for the first nine months of this year were $50.7 million compared to $66.6 million for the 2002 period, a 24% decrease. These reductions are the result principally of the company's efforts over the past year to take advantage of investments in automation in its gene research programs and to focus resources on product development.

Selling, general and administrative expenses for the third quarter decreased by 31% versus last year, to $4.0 million for the period in 2003 from $5.8 million for the period in 2002. SG&A expenses for the first nine months of 2003 were $12.0 million, compared to $14.2 million for the first nine months of 2002, representing a decrease of 16%. These decreases are principally due to the streamlining of the company's operations undertaken last year.

At the close of the third quarter, the company had $78.4 million in cash and cash equivalents, including $6 million in restricted cash. This is $1.8 million more than at the close of the second quarter, an increase resulting mainly from the significantly lower net loss for the quarter and the collection of receivables.

"Our strong results for the quarter are the fruit of our efforts to accelerate our target discovery work and to channel our resources directly into product development. By maintaining our focus on increasing revenue while driving down costs, we have achieved positive cashflow from our current operations for the quarter and have in hand the resources necessary to bring our lead therapeutic and diagnostic products into the clinic," said Dr. Kari Stefansson, President and Chief Executive Officer of deCODE. "In recent weeks we have announced several examples of how our genetics work is yielding exciting new targets for both drug and diagnostic development. The coming months promise to be an important period in deCODE's growth and I look forward to sharing with you our progress in advancing our product pipeline. Our successes this year have positioned us well to take a leading role in applying the new genetics to improve the diagnosis, treatment and prevention of many of the most common diseases in our society."

   Recent company highlights include:

   Research and Development

    * Obesity.  deCODE announced the achievement of a milestone under its
      alliance with Merck to develop novel treatments for obesity.  Through
      genotypic analysis involving more than 1000 women participants in its
      obesity program, deCODE scientists isolated a gene which in one form
      predisposes to obesity and in another form predisposes to thinness.
      The companies are using this information in their drug discovery
      program.

    * Myocardial infarction.  deCODE and Roche Diagnostics announced a
      landmark discovery under their alliance to develop DNA-based diagnostic
      tests for common diseases.  deCODE scientists identified forms of a
      gene that confer approximately twice the average risk of myocardial
      infarction, or heart attack.  The companies plan to use this
      information in the development of a DNA-based test to identify
      individuals who are at elevated risk, thereby facilitating the
      implementation of preventive measures that can help to minimize the
      risk of these individuals ever suffering a heart attack.  The two
      at-risk haplotypes, or forms of the gene, each delineated by only 6
      SNPs, are both common and were found to confer significant risk of
      heart attack in the Icelandic population.  These haplotypes confer
      risks equal to or greater than those conferred by other well-known risk
      factors such as smoking, high blood pressure, high cholesterol or
      diabetes.

    * Stroke.  deCODE's study identifying the first gene ever linked to
      common forms of stroke was published in the October edition of Nature
      Genetics, in a paper entitled "The Phosphodiesterase 4D gene confers
      risk to ischemic stroke."  The deCODE team identified the PDE4D gene
      and significant haplotypes by analyzing detailed genotypic data from
      1800 participants in the company's stroke program, both patients and
      unaffected relatives, from across Iceland.  The study demonstrates that
      variations in the PDE4D gene are significantly associated with ischemic
      stroke.  Within this gene, the deCODE team identified haplotypes, or
      specific sets of genetic markers, that correspond both to significantly
      increased risk of stroke and to significantly decreased risk.  deCODE
      and its drug development partner in this program, Roche, have initiated
      medicinal chemistry work on compounds they have identified as active
      against targets in the PDE4D pathway.  deCODE is also developing a
      DNA-based diagnostic test based upon the at-risk and protective
      haplotypes within the PDE4D gene.

   Finance

    * Cash position.  At the close of the quarter ended September 30, 2003,
      the company had $78.4 million in cash and cash equivalents, including
      $6 million in restricted cash.  This is $1.8 million more than at the
      close of the second quarter, an increase resulting mainly from the
      significantly lower net loss for the quarter and the collection of
      receivables.


About deCODE

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services -- in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE's pharmaceuticals group, based in Chicago, and deCODE's biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE's proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at www.decode.com.

Conference Call Information

A conference call, during which deCODE President and CEO Kari Stefansson and Executive Vice President and Senior Business Officer Hannes Smarason will discuss financial results and operating highlights from the quarter, will be webcast tomorrow, Thursday, October 30, at 8am EST/1pm GMT. The webcast can be accessed via the Investors section of deCODE's website, www.decode.com, through www.streetevents.com, or, for non-subscribers to StreetEvents, on www.companyboardroom.com. A replay of the call will be available on these websites for the following week. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1 800 475 6701 from the US, or +1 320 365 3844 from outside the US. The access code is 703702.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

        Condensed Consolidated Statements of Operations (unaudited)

                               For the three months      For the nine months
                                ended September 30,      ended September 30,
                                 2003         2002          2003       2002
                           (in thousands, except share and per share amounts)
   Revenue                    $  12,763  $     8,982  $    35,141  $  23,682
   OPERATING EXPENSES
       Research and
        development, including
         cost of revenue         11,068       23,856       47,516     66,634
       Selling, general and
        administrative            3,989        5,753       11,975     14,235
       Impairment, employee
        termination costs and
         other charges              115       64,790          906     64,790
             Total operating
              expense            15,172       94,399       60,397    145,659
   Operating loss                (2,409)     (85,417)     (25,256)  (121,977)
   Interest income                  243          711          897      2,269
   Interest expense                (826)        (589)      (2,603)    (2,199)
   Other non-operating income
    and (expense),  net           1,706         (144)       2,402        560
   Net loss before cumulative
    effect of change in
     accounting principle        (1,286)     (85,439)     (24,560)  (121,347)
   Cumulative effect of change
    in milestone recognition
     method                           0            0            0        333
   Net loss                   $  (1,286) $   (85,439)$    (24,560)$ (121,014)

   Basic and diluted net loss
    per share:
       Net loss before
        cumulative effect of
         change in accounting
          principle           $   (0.03) $     (1.68)$      (0.48)$    (2.51)
       Cumulative effect of
        change in milestone
         revenue recognition
          method              $      --  $        -- $         -- $     0.01
       Net loss               $   (0.03) $     (1.68)$      (0.48)$    (2.50)
   Shares used in computing
    basic and diluted net
     loss per share          51,399,816   50,958,332   51,262,995 48,425,673


    Contact:
    deCODE genetics
    Joy Bessenger            Edward Farmer
    +354 570-1951            +354 570 1900
    +1 (212) 481-3891        info@decode.is
    ir@decode.is




--------------------------------------------------
Source: deCODE genetics

Email this story - Set a News Alert

 

12.11.03 14:53

3515 Postings, 7290 Tage baanbruchXOMA financials (Kurztext)

7:38AM XOMA Limited misses by $0.02, beats on revs (XOMA) 6.84: Reports Q3 (Sep) loss of $0.13 per share, $0.02 worse than the Reuters Research consensus of ($0.11); revenues rose 198.6% year/year to $12.6 mln vs the $10.4 mln consensus.

 

12.11.03 14:54

3515 Postings, 7290 Tage baanbruchdeCode knackt die 7 Euro (und wird drüber bleiben) o. T.

13.11.03 20:35

3515 Postings, 7290 Tage baanbruch9 Dollar? Groovy, shaggadelic !

Na ja, 20 cents fehlen noch!
News hierfür habe ich keine.
Die Ankündigung der Konferenz reicht ja wohl nicht.

deCODE genetics to Webcast R&D Day
Thursday November 13, 8:12 am ET


REYKJAVIK, Iceland, Nov. 13 /PRNewswire-FirstCall/ -. deCODE genetics (Nasdaq: DCGN - News) today announced that it will webcast live the presentations at its first annual U.S. R&D Day to be held next week in New York City. deCODE management will provide an in-depth discussion of the company's population genetics work and drug and diagnostics development programs.
The event will take place on Wednesday, November 19, 2003, and speakers will include Kari Stefansson, President and Chief Executive Officer; Jeffrey Gulcher, Vice President of Research and Development; Mark Gurney, Vice President of Drug Discovery; and Hakon Hakonarson, Vice President of Clinical Development. The presentations are scheduled to begin at 9am EST/2pm GMT and conclude at 12:30pm EST/5:30pm GMT. The webcast can be accessed through the Investors page on deCODE's website, www.decode.com, or through www.fulldisclosure.com. Those interested in listening to the presentation should log on a few minutes in advance, in order to download any software or complete any sign-in that may be required.

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services -- in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE's pharmaceuticals group, based in Chicago, and deCODE's biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE's proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at www.decode.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contact:
    deCODE genetics
    Kristin Asgeirsdottir      Joy Bessenger
    +354 570 1950              +1 212 481 3891
    ir@decode.is               ir@decode.is




--------------------------------------------------
Source: deCODE genetics
 

13.11.03 20:42

3515 Postings, 7290 Tage baanbruchOder sollte es das hier sein ?

LIQUIDITY AND CAPITAL RESOURCES




We have financed our operations primarily through funding from collaborative agreements and the issuance of equity securities and
debt instruments ($486 million from the beginning of 1999 to-date). As of September 30, 2003, future funding under terms of our existing agreements is approximately $50 million excluding milestone payments and royalties that we may earn under such collaborations.



Cash and Cash Equivalents. As of September 30, 2003, we had $78.4 million in cash and cash equivalents, including $6 million of restricted cash. Available cash is invested in accordance with our investment policy's primary objectives of liquidity, safety of principal and diversity of investments. Our cash is deposited only with financial institutions in Iceland, the United Kingdom and the United States having a high credit standing. This cash is largely invested in U.S. dollar denominated money market and checking accounts and also in Icelandic krona denominated accounts.



Operating Activities. Working capital needs resulted in $1.7 million of funds used in the nine-month period ended September 30, 2003 and provided $2.8 million in the nine-month period ended September 30, 2002. Net cash used in operating activities decreased $26.5 million in the nine-month period ended September 30, 2003 as compared to the nine-month period ended September 30, 2002. As more fully described above, this is as a result of our increased revenue base and the impacts of the cost reduction measures we implemented late in 2002.



Investing Activities. Our investing activities have consisted of capital expenditures and long-term strategic equity investments in, and acquisitions of, technologies and businesses that are complementary to our business. Purchases of property and equipment during the nine-month period ended September 30, 2003 were $0.7 million as compared to $14.1 million in the nine-month period ended September 30, 2002. We principally made replacement capital expenditures during the nine-month period ended September 30, 2003. During the nine-month period ended September 30, 2002 we expended $5.7 million in respect of the new building, $2.8 million for the purchase of DNA analyzers under our supply agreement with ABG and acquired $3.3 million of cash in the purchase of MediChem. There were also $3.9 million of MediChem transaction costs, resulting in a net outlay of cash for the nine month period ended September 30, 2002 in connection with the acquisition of $0.6 million. Although we expect to continue to make simply replacement capital expenditures, net cash used in investing activities may in the future fluctuate significantly from period to period due to the timing of our capital expenditures and other investments.



Financing Activities. Net cash of $1.7 million was provided by financing activities in the nine-month period ended September 30, 2003 as compared to $2.9 million provided in the nine-month period ended September 30, 2002. Financing activities for the nine-month period ended September 30, 2003 largely consisted of the sale and 18-month leaseback of certain laboratory equipment ($4.8 million), short-term borrowings ($2.0 million) and installment payments on our existing debt and capital lease obligations ($5.3 million). In December 2001, we established a $27.5 million bridge loan with an Icelandic financial institution to finance the construction of our new headquarters facility. We repaid the borrowings under the bridge loan in January and March 2002 with the proceeds from our Tier A $13.5 million bond offering, Tier C $7.3 million offering of privately placed bonds and Tier D $6.7 million bank loan. $14 million of cash that was restricted as of December 31, 2001 was provided in 2002 in the final financing (Tiers C and D) of our new headquarters facility.



We seek to maintain a desired level of floating-rate debt with respect to our overall debt portfolio denominated in U.S. Dollars. To this end, we have entered into two interest rate and cross-currency swaps to manage interest rate and foreign currency risk arising from long-term debt obligations denominated in Icelandic krona. These interest rate and cross-currency swaps with a remaining combined notional amount of 1,930 million Icelandic krona are designated as economic hedges of fixed rate foreign currency debt (Tier A and Tier C bonds), but do not qualify for hedge accounting under SFAS 133. The estimated fair value of these instruments is included in other long-term assets is $10.7 million and $6.4 million as of September 30, 2003 and December 31, 2002, respectively. The unrealized gain for the nine-month periods ended September 30, 2003 and 2002 resulting from the recording of these instruments together with the translation of the Tier A and Tier C bonds is $2.4 million and $1.6 million, respectively, and is included in other non-operating income and (expense), net in the Consolidated Statements of Operations.



General. Following the implementation in September 2002 of a plan to reduce headcount and maximize the use of automation in our core genetics operations and based upon current plans, we believe that our existing resources will be adequate to satisfy our capital needs for several years. Our cash requirements depend on numerous factors, including our ability to obtain new research collaboration agreements, to obtain subscription and collaboration agreements for the database services; to obtain and maintain contract service agreements in our chemistry services and clinical research trials groups; expenditures in connection with alliances, license agreements and acquisitions of and investments in complementary technologies and businesses; competing technological and market developments; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; the purchase of additional capital equipment, including capital equipment necessary to ensure that our sequencing and genotyping operations remain competitive; and capital expenditures required to expand our facilities. Changes in our research and development plans, the entry into clinical trials of a drug based on our discoveries, or other changes affecting our operating expenses may result in changes in the timing and amount of expenditures of our capital resources.



We will require significant additional capital in the future, which we may seek to raise through further public or private equity offerings, additional debt financing or added collaborations and licensing arrangements. No assurance can be given that additional financing or collaborations and licensing arrangements will be available when needed, or that if available, will be obtained on favorable terms. If adequate funds are not available when needed, we may have to curtail operations or attempt to raise funds on unattractive terms.


 

14.11.03 22:22

3515 Postings, 7290 Tage baanbruchNoch 4 cents ! (gegen 20:00 schon mal 9.19!) o. T.

17.11.03 15:13

3515 Postings, 7290 Tage baanbruchVerkehrte Welt: deCode zahlt an Bayer ! ?

REYKJAVIK, Iceland, Nov. 16 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN - News) today announced that it has acquired an exclusive worldwide license from Bayer AG to develop and commercialize a small molecule compound. The compound is active against a key target, located within an inflammatory pathway, made by a gene isolated at deCODE that predisposes to myocardial infarction, or heart attack. The compound, DG031, has been shown in previous clinical work in a different indication to be well-tolerated and with no major safety issues. deCODE plans to test it for efficacy in preventing heart attack in an information-rich Phase II clinical trial, enrollment for which is expected to start at the beginning of next year. deCODE plans to provide additional detail on the target and the compound in a scientific article to be submitted at the beginning of the clinical trial. Bayer will receive milestones as the compound advances towards market approval, as well as royalties on sales of the compound as a marketed drug.

Der Originaltext ist noch wesentlich länger, aber das reicht ja schon mal als Info
oder?

Ob der Kurs auch heute - trotz des Umfelds - noch weiter steigt?
Bekomme langsam Höhenangst.
Aber - wir sind noch nicht zweistellig!
 

16.01.04 00:45

3515 Postings, 7290 Tage baanbruchGibt es auch zweijährige Untertassen ?

Bzw. 2-Jahres-Untertassen?

Und heute nachmittag hätte man in Frankfurt noch für
unter 7 Euro nachkaufen können!

deCode Nasdaq Schluß heute bei 9,90 = 52 Wochen hoch
und wohl auch 2-Jahres-Hoch (oder nah dran).
 

16.01.04 22:32

3515 Postings, 7290 Tage baanbruchAnd then there were two

digits !

Über 10 Dollar.
Mir gefällt´s.
 

05.02.04 17:15

3515 Postings, 7290 Tage baanbruchAchtung: bei DeCode könnte es Ärger geben !

Habe gerade aus dem Norden gehört, daß dort eine
obskure Geldzahlung aus dem Jahr 1999 durch die
Presse geht.

In USA hat das z.Zt. noch keine Auswirkungen auf
den Kurs (nur knapp im Minus).

Was mir nicht gefällt, ist, daß wohl aus dem
Headquarter von DeCode keine Erklärung kommt.

Also, wer sie hat, vielleicht mit S/L absichern ?

Ich selber werde drin bleiben.
 

11.02.04 23:30

3515 Postings, 7290 Tage baanbruchKein Ärger sondern neues ATH .

Morgen dürfte es eigentlich keine Stücke
mehr in FRA unter 10 Euro geben.
Allerdings war bisher die Euphorie in BRD bezgl.
DeCode schon immer eher etwas gebremst.
Schau´n wer mal.
Bißken Liqui mal wieder wäre nicht schlecht !
 

18.02.04 00:18

3515 Postings, 7290 Tage baanbruchEnde ohne Schrecken

Ich will diesen thread hier mal ausklingen lassen.
Wenn mir was neues zu DCGN einfällt (oder auch zu XOMA),
mache ich was neues auf. Fips17 hatte das hier gestartet,
ich hab´s dann umgemünzt. Wird aber langsam zu lang und unübersichtlich,


DCGN hat heute abend Zahlen in USA gemeldet, die wohl recht gut
waren. Im Vorfeld zog der Kurs abermals bis weit über 13 Euro an.
Gleichzeitig wurde der Kurs in Euro erstmals nach Jahren wieder
zweistellig in BRD. Ein lang ersehntes Ziel wurde wahr und ich
habe einen Teil meiner Goldstücke verkauft.
Keine Ahnung wie es morgen weiter geht. Ob "sell on good news" greift
oder die Aktie jetzt immer "ernster" genommen wird.
Schön war´s in letzter Zeit.

Wenn doch Börse nur öfter so befriedigend wäre!
 

08.10.08 17:23

3515 Postings, 7290 Tage baanbruchWeiter geht es in einem anderen Thread


Und zwar dem hier, gestartet von centy01:

http://www.ariva.de/DECODE_GENETICS_Rebound_t342645#jump4807804

 

Seite: 1 | 2 | 3 | 4 | 4   
   Antwort einfügen - nach oben